文献速递妇科

「大家听到的都是简化语言」:卵巢癌患者对生物标志物检测的看法

"What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-08-22

研究通过2023年10月至11月的三场线上焦点小组访谈,纳入7名晚期卵巢癌患者(平均62岁;85%为非西班牙裔白人,15%为亚裔),探讨其对遗传与生物标志物检测的认知与体验。患者对遗传检测(尤其BRCA)理解较强,对生物标志物检测知识有限,经济与保险问题及对检测与治疗、家族风险相关性的困惑构成障碍;医患沟通良好是促进因素。作者认为加强生物标志物检测教育并提供针对性经济援助可能改善患者理解与可及性。

要点

  • 患者对遗传检测(尤其BRCA)理解较强,对生物标志物检测知识有限。
  • 经济负担、保险问题及对检测与治疗和家族风险相关性的困惑是障碍。
  • 良好的医患关系与清晰沟通是支持患者参与检测的促进因素。

核心结论

  • 患者指出遗传与生物标志物检测存在经济限制、保险覆盖及对生物标志物与治疗和家族风险相关性认识不清等障碍;良好的医患关系与清晰沟通是促进因素。
  • 作者认为加强生物标志物检测教育并提供针对性经济援助可能改善患者理解与获取这些诊断工具。

研究设计与样本

  • 招募卵巢癌患者参加线上焦点小组,评估其对遗传与生物标志物检测的经历与知识,聚焦恐惧、知识、经济问题及医患沟通等主题。
  • 由三名团队成员采用主题分析法对焦点小组进行编码。

主要发现

  • 2023年10月至11月开展三场焦点小组,共7名晚期卵巢癌患者参加,平均年龄62岁,85%为非西班牙裔白人,15%为亚裔。
  • 85%的参与者同时接受过遗传检测和生物标志物检测。
  • 参与者对遗传检测尤其BRCA理解较强,而对生物标志物检测的知识有限。
  • 参与者强调临床医生沟通在遗传与生物标志物检测中的重要性,并强调需要就检测与治疗的相关性提供指导。
  • 经济顾虑、保险问题及对生物标志物检测潜在家族影响的困惑成为障碍;参与者认为此类检测在决定治疗选择和家族风险评估中具有关键作用。

临床怎么用

  • 作者认为改善生物标志物检测教育并提供针对性经济援助可能增强患者理解与获取这些关键诊断工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the views of patients with ovarian cancer on biomarker (somatic) and genetic testing and existing patient-facing materials. METHODS: We recruited patients with ovarian cancer for virtual focus groups and assessed patient experiences and knowledge of genetic and biomarker testing. We focused on themes of fear, knowledge, financial issues, and communication between patients and providers. Three team members coded focus groups using a thematic approach. RESULTS: In October-November 2023, three focus groups were conducted, comprising seven participants with advanced ovarian cancer (mean 62 years; 85 % Non-Hispanic White, 15 % Asian). 85 % had undergone both genetic and biomarker testing. Participants displayed a stronger understanding of genetic testing, particularly BRCA, while biomarker testing knowledge was limited. Findings highlighted the importance of clinician communication in navigating genetic and biomarker testing, with participants emphasizing the need for guidance on the relevance of tests to treatment. Financial concerns, insurance issues, and confusion about the potential familial impact of biomarker testing emerged as barriers. Participants expressed a belief in the critical role of such testing in shaping treatment options and in familial risk assessment. CONCLUSIONS: Patients identified several barriers to genetic and biomarker testing, including financial constraints, insurance coverage, and lack of clarity about the relevance of biomarkers to their treatment and familial risk. Conversely, a strong provider-patient relationship and clear communication were facilitators that supported patient engagement with testing (e.g., decision-making about testing, follow through with testing). Improving education on biomarker testing and offering targeted financial assistance may enhance patient understanding and access to these critical diagnostic tools in ovarian cancer care.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Smith AJ, Acharya R, Ang L, et al. "What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer. Gynecol Oncol. 2025. PMID: 40848682. doi:10.1016/j.ygyno.2025.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。